Industry Experts

Mitchell spent 3.5 years as a medicinal chemist researching and developing central nervous system drug candidates for neurodegenerative diseases in the Lab for Drug Discovery in Neurodegeneration at Brigham and Women’s Hospital/ Harvard Medical School. Following, Mitchell served as co-founder and Chief Technology Officer for 2.5 years at Modulate Bio, where he helped develop next-gen GABA-A positive allosteric modulators to treat neurological disorders, including essential tremor, epilepsy, and anxiety. Mitchell now works as an Application Scientist at Collaborative Drug Discovery